In Brief This Week: Sequenom; Geneart, Life Technologies; Thermo Fisher Scientific; Spartan Bioscience; BioTime | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom this week said that it will begin a validation study of its SensiGene T21 Laboratory-Developed Test in January. The firm has received its first set of clinical samples and will conduct the study at its reference lab, the Sequenom Center for Molecular Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.